Camurus AB (publ) (CAMRF)

Market Cap	4.49B +31.8%
Revenue (ttm)	242.79M +3.0%
Net Income	75.69M -3.3%
EPS	1.28 -4.2%
Shares Out	n/a
PE Ratio	56.00
Forward PE	36.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	71.90
Previous Close	71.90
Day's Range	71.90 - 71.90
52-Week Range	54.00 - 71.90
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 316
• Stock Exchange: OTCMKTS
• Ticker Symbol: CAMRF

Financial Performance

In 2025, Camurus AB's revenue was 2.27 billion, an increase of 21.30% compared to the previous year's 1.87 billion. Earnings were 735.57 million, an increase of 71.70%.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error